Medicaid Coverage of and Spending on GLP-1s ++++

Medicaid Coverage of and Spending on GLP-1s Jan 16, 2026 Issue Brief https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/ This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s. The ‘Great Healthcare Plan’ Leaves Open Questions for People with Pre-existing Conditions Jan 16, 2026 https://www.kff.org/quick-take/the-great-healthcare-plan-leaves-open-questions-for-people-with-pre-existing-conditions/ President Trump announced a health care framework that leaves open key questions, including those about out-of-pocket costs, premiums, federal spending, and health coverage for people with pre-existing conditions. President Trump Proposes Codifying MFN Drug Pricing Deals But Key Details Are Missing Jan 15, 2026 https://www.kff.org/quick-take/president-trump-proposes-codifying-mfn-drug-pricing-deals-but-key-details-are-missing/ While codifying most-favored-nation drug pricing could be helpful for bringing more transparency to these arrangements and guaranteeing that drug companies will deliver on what they’ve promised, policymakers would need substantially more information to turn these backroom voluntary deals into law. Senators’ Questions About Mifepristone Could Further Spread Confusion About the Abortion Pill’s Safety Record Jan 15, 2026 https://www.kff.org/quick-take/senators-questions-about-mifepristone-could-further-spread-confusion-about-the-abortion-pills-safety-record/ By suggesting mifepristone poses a danger to women who use it, anti-abortion senators are likely to create more confusion that could further erode the public's confidence in the abortion pill despite its decades-long safety record.